Organobalance inks deal with Sanofi; Most childhood vaccines not linked to bleeding disorder;

> Sanofi Pasteur has inked a licensing deal with Germany's Organobalance that gives Sanofi access to a modified yeast strain for use in vaccines. Release

> A study conducted at Children's Hospital Colorado in Aurora found that most childhood vaccines are not associated with an increased risk of developing thrombocytopenic purpura (ITP), a bleeding disease. The MMR vaccine has been known to trigger the condition in rare cases. Report

> A single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced immune responses, says Colby Pharmaceutical. The findings were published in the journal Vaccine. Release

> Diamyd has enrolled 50 children aged 4 and older in a Phase II study of the company's vaccine Diamyd. Researchers hope to learn whether the vaccine will prevent kids who are at risk for Type 1 diabetes from developing the disease. Release

> Sinovac Biotech has initiated a Phase III clinical trial of its inactivated EV71 vaccine against hand, foot and mouth disease. Release

And Finally... China's SFDA says it's approved the world's first hepatitis E vaccine, which was developed by researchers at Xiamen University and Xiamen Innovax Biotech. The developer will market the vaccine to those at risk of contracting the disease, and plans to introduce the shot in other countries. Article

Suggested Articles

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.